Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Systane · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Systane |
| 2 | EXPERIMENTAL | Blink tears |
| Name | Type | Description |
|---|---|---|
| (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400 | DRUG | Drops |
| Systane | DRUG | Drops |
Inclusion Criteria: * Mild to moderate dry eye * over 18 Exclusion Criteria: * No concurrent ocular disease or meds
Systane is used for the treatment of dry eye. It is an investigational small molecule being developed by Abbott Laboratories for patients with mild to moderate dry eye. The drug is currently in Phase 2 clinical development, meaning it has not yet been approved by regulatory authorities.
Systane is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. The drug is currently in Phase 2 clinical trials for the treatment of dry eye, and it is not yet approved for commercial use.
Systane is in Phase 2 clinical development for the treatment of dry eye. It is an investigational drug, meaning it has not been approved by regulatory agencies. The Phase 2 trial has been completed, and the drug is not currently in any active clinical trials.
Systane has been studied in one completed Phase 2 clinical trial, registered under the identifier NCT00607776. This trial, titled "Artificial Tears Study in Mild to Moderate Dry Eye Patients," enrolled 110 participants and was a randomized, double-blind, active-controlled study. The trial is now completed.
Systane is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of dry eye. The Phase 2 trial has been completed, but the drug has not yet received regulatory approval and remains in clinical development.